GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Other Current Receivables

Purple Biotech (XTAE:PPBT) Other Current Receivables : ₪0.00 Mil (As of Mar. 2025)


View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Other Current Receivables?

Purple Biotech's Other Current Receivables for the quarter that ended in Mar. 2025 was ₪0.00 Mil.

Purple Biotech's annual Other Current Receivables declined from Dec. 2022 (₪3.53 Mil) to Dec. 2023 (₪0.73 Mil) but then increased from Dec. 2023 (₪0.73 Mil) to Dec. 2024 (₪0.97 Mil).


Purple Biotech Other Current Receivables Historical Data

The historical data trend for Purple Biotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Other Current Receivables Chart

Purple Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.76 3.56 3.53 0.73 0.97

Purple Biotech Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.97 -

Purple Biotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Purple Biotech Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Purple Biotech Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.